Wells Fargo lowered the firm’s price target on Viridian Therapeutics (VRDN) to $37 from $39 and keeps an Overweight rating on the shares. The firm remains positive on VRDN-001’s odds of success in both of its Phase 3 trials in active and chronic TED, which will read out this year. Additionally, Acelyrin’s (SLRN) lonig data in TED and NHP data for VRDN-008 are potential trading catalysts, Wells says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Therapeutics expects cash to fund operations into second half of 2026
- Viridian Therapeutics reports Q4 EPS ($1.35), consensus ($1.00)
- Viridian Therapeutics names Jennifer Tousignant chief legal officer
- Insider Trading: Viridian (NASDAQ:VRDN) Sees Huge Insider Buy
- Viridian Therapeutics price target lowered to $39 from $40 at Wedbush
